Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10308961

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10307386

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10308591

    Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10307477

    Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

    The United States of America as represented by the Secretary of the Army · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10307484

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10307491

    Liposomal particles comprising biological molecules and uses thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10307579

    Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10307415

    Epimorphic regeneration and related hydrogel delivery systems

    Northwestern University · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10307410

    Mcl-1 modulating compounds for cancer treatment

    INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10307398

    Resuscitation composition and methods of making and using

    Regents of the University of Minnesota · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10307416

    Oligomer-opioid agonist conjugates

    Nektar Therapeutics · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10307414

    Pyridinyl and fused pyridinyl triazolone derivatives

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10307428

    Therapeutic compositions for diabetic symmetrical polyneuropathy

    The Regents of the University of California · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10307449

    Compositions of polymeric myrcene

    REGENERA PHARMA LTD. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10306874

    Non-human animals having a humanized lymphocyte-activation gene 3

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10307437

    Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10307476

    Genetically stable live attenuated respiratory syncytial virus vaccine and its production

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10308643

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10308708

    Antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10308608

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10307481

    CD37 immunotherapeutics and uses thereof

    Aptevo Research and Development LLC · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10308609

    Bicyclic compounds

    Zeno Royalties & Milestones, LLC · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10308617

    Triazole benzamide derivatives and the compositions and methods of treatment regarding the same

    AN2H DISCOVERY LIMITED · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10307444

    Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

    Astellas Institute for Regenerative Medicine · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10308635

    1-sulfonyl piperidine derivatives as modulators of prokineticin receptors

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10308658

    Salt of EGFR inhibitor, crystalline form and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10308720

    Multivalent and multispecific DR5-binding fusion proteins

    Inhibrx, Inc. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10308934

    Compositions for modulating Ataxin 2 expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10308941

    Compositions and methods for inhibiting gene expression of factor XII

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10308698

    Therapeutic targeting of SET1B/compass pathway for treating cancers

    Northwestern University · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10308638

    Selective alpha-7 nicotinic receptor agonists and methods for making and using them

    The Regents of the University of California · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10308909

    Dried spore germinative compound mixtures

    Envera LIC, LLC · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10307469

    Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10307423

    FBXO3 inhibitors

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10308927

    Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease

    The United States of America, as represented by the Secretary of Homeland Security · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10307418

    Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds

    Platform Brightworks Two, Ltd. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10308646

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10307407

    9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10308605

    Proton pump inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10307388

    Compositions and methods for diagnosis and treatment of inflammation

    United States of America as represented by the Secretary of the Air Force · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. CA 3079530

    COMPOSITION LIQUIDE STABLE DE KETOPROFENE, SELS ET ENANTIOMERES DE CELUI-CI

    ACRAF [IT] · Granted Thu Jun 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10314850

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Corcept Therapeutics Incorporated · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10314904

    Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10314837

    Subcutaneous delivery of poly(oxazoline) polymer conjugates

    Serina Therapeutics, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10315984

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10316371

    Screening methods for identifying specific Staphylococcus aureus inhibitors

    TRANA DISCOVERY, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10316073

    FCRN antagonists and methods of use

    The Board of Regents of the University of Texas System · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10314769

    Organic-inorganic composite particles and cosmetic product

    JGC Catalysts and Chemicals Ltd. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.